Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Harvoni 45 mg/200 mg film-coated tablets

Active Ingredient:
sofosbuvir , ledipasvir
Company:  
Gilead Sciences Ltd See contact details
ATC code: 
J05AP51
{info_black}
About Medicine
{medical_services}
Prescription only medicine
Healthcare Professionals (SmPC) Patient Leaflet (PIL) Letters to HCPs HCP Med Info
{arrow_left}
{arrow_right}

Important information for Healthcare Professionals

{pdf_link}

Harvoni 45 mg/200 mg film-coated tablets UK DHPC 22-Oct-2020

{healthcare_pro_orange} For Healthcare Professionals
Direct Healthcare Professional Communication on labelling exemption for Harvoni 45 mg/200 mg film-coated tablets due to supply disrupution in the UK. MHRA approval for use in UK of product packaged originally for the Irish market until 31 December 2020.

You are trying to reach document intended for healthcare professionals only.

Are you a healthcare professional?

Log in or sign up to avoid further verifications.

Gilead Sciences Ltd
Company image
Address
280 High Holborn, London, WC1V 7EE, UK
Telephone
+44 (0)203 681 4500
E-mail
[email protected]
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)203 681 4681
Customer Care direct line
+353 1 291 3580 (Ireland)
Medical Information Direct Line
08000 113 700 (UK)
Medical Information Direct Line
+353 214 825 999 (Ireland)